Bronchopulmonary Dysplasia (BPD) – Epidemiology Insights and Disease Burden Report – 2020 To 2040
- Published Date : November 14, 2025
- Updated On : June 17, 2026
- Pages : 52
Bronchopulmonary Dysplasia (BPD) Epidemiology Insights and Disease Burden
Thelansis’s “Bronchopulmonary Dysplasia (BPD) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Bronchopulmonary Dysplasia (BPD) Overview
Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease of prematurity driven by arrested alveolar and vascular development, compounded by oxygen toxicity, mechanical ventilation, and systemic inflammation. Unlike “classical” BPD, the modern phenotype features simplified alveolarization and dysmorphic vasculature. Diagnosis relies on respiratory support requirements at 36 weeks postmenstrual age. Management centers on lung-protective non-invasive ventilation, caffeine, and nutritional optimization. Because systemic postnatal corticosteroids carry severe neurodevelopmental risks, protocols increasingly utilize intratracheal budesonide delivered via surfactant to safely suppress early inflammation. Severe BPD with pulmonary hypertension warrants targeted vasodilators like sildenafil. Crucially, viral prophylaxis has shifted to nirsevimab, a long-acting monoclonal antibody providing season-long RSV protection in a single dose. While current care remains largely supportive, the advanced clinical pipeline is actively evaluating regenerative therapies, specifically mesenchymal stromal cell (MSC) infusions, to structurally restore lung architecture.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
Bronchopulmonary Dysplasia (BPD) Epidemiology Insights and Disease Burden
Thelansis’s “Bronchopulmonary Dysplasia (BPD) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies.
Bronchopulmonary Dysplasia (BPD) Overview
Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease of prematurity driven by arrested alveolar and vascular development, compounded by oxygen toxicity, mechanical ventilation, and systemic inflammation. Unlike “classical” BPD, the modern phenotype features simplified alveolarization and dysmorphic vasculature. Diagnosis relies on respiratory support requirements at 36 weeks postmenstrual age. Management centers on lung-protective non-invasive ventilation, caffeine, and nutritional optimization. Because systemic postnatal corticosteroids carry severe neurodevelopmental risks, protocols increasingly utilize intratracheal budesonide delivered via surfactant to safely suppress early inflammation. Severe BPD with pulmonary hypertension warrants targeted vasodilators like sildenafil. Crucially, viral prophylaxis has shifted to nirsevimab, a long-acting monoclonal antibody providing season-long RSV protection in a single dose. While current care remains largely supportive, the advanced clinical pipeline is actively evaluating regenerative therapies, specifically mesenchymal stromal cell (MSC) infusions, to structurally restore lung architecture.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Deliverables format and updates*:
- Access to an interactive epidemiology platform with downloadable Excel and PPT files.
- Global findings
- G8 findings
- Regional findings
- Country-specific findings
- Others*: regular updates, customizations, epidemiologist support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.
Key business questions answered:
- 20-year historical and forecast data (2020–2040)
- Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
- Granular patient population coverage by year and geography
- Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
- Patient funnels
- Country comparisons
- Relevant clinical variables (e.g., staging/classification/severity)
Insights driven by robust research and estimates:
- Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
- Primary market research with KOLs
- RWD analysis using claims and EHR datasets
- Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)